2023 World Conference on Lung Cancer (Posters)-EP11.01. Clinical Significance of Soluble PD-1 and PD-L1 in Plasma of NSCLC Patients Treated with Immune Checkpoint Inhibitors

EP11.01. Clinical Significance of Soluble PD-1 and PD-L1 in Plasma of NSCLC Patients Treated with Immune Checkpoint Inhibitors - PDF(Slides)

Back to course

Pdf Summary

A study investigated the clinical significance of soluble PD-1 (sPD-1) and soluble PD-L1 (sPD-L1) in the plasma of non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs). The study aimed to determine the clinical roles of these biomarkers before and after ICI treatment, particularly in patients receiving ICI monotherapy versus combination therapy. <br /><br />The study included NSCLC patients who received anti-PD-1 or anti-PD-L1 antibodies at two cancer centers in Japan. Blood samples were collected before and six weeks after the start of ICI treatment. The levels of sPD-1 and sPD-L1 were measured using ELISA, and other soluble immune mediators were assessed using multiplex assays. <br /><br />The results showed that higher levels of sPD-L1 before treatment were associated with unfavorable progression-free survival (PFS) and overall survival (OS) in patients treated with ICI monotherapy. This suggests that sPD-L1 may compete with ICI and promote T cell exhaustion by binding to PD-1 on T cells. Additionally, post-treatment levels of sPD-1 and sPD-L1 were also associated with OS in patients receiving ICI monotherapy. Higher levels of sPD-1 and lower levels of sPD-L1 after treatment were linked to better efficacy of anti-PD-1 antibodies. <br /><br />The study also found a correlation between sPD-L1 and other soluble receptors, such as sCD30, sTNF-R1, sTNF-R2, and IL-2Ra, in plasma before treatment. These receptors are released from the cell surface through shedding by ADAM10 and ADAM17 proteases. The high correlations between sPD-L1 and these receptors suggest their collaborative modulation of the immune microenvironment. <br /><br />In conclusion, the study suggests that pre-treatment levels of sPD-L1 are predictive of response to ICI monotherapy in NSCLC patients. Monitoring changes in sPD-1 and sPD-L1 levels during ICI monotherapy can also provide insight into patient outcomes. These findings may contribute to the development of predictive biomarkers and potential combination therapies for NSCLC patients receiving ICIs.

Asset Subtitle

Yoshiro Nakahara

Meta Tag

Speaker Yoshiro Nakahara

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

soluble PD-1

sPD-1

soluble PD-L1

sPD-L1

non-small cell lung cancer

NSCLC

immune checkpoint inhibitors

ICI

combination therapy

biomarkers